Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07057791 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer
A Phase 2 study of Extensive Stage Lung Small Cell Cancer, sponsored by PrECOG.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT07057791: Recruiting Phase 2 study of Extensive Stage Lung Small Cell Cancer, sponsored by PrECOG.
NCT07057791 is a Phase 2 study of Extensive Stage Lung Small Cell Cancer that is actively recruiting participants, run by PrECOG. The registered enrollment target is 60 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07057791, a Phase 2 study of Extensive Stage Lung Small Cell Cancer, is actively recruiting participants, sponsored by PrECOG.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Eligible untreated participants with Extensive Stage Small Cell Lung Cancer (ES-SCLC) who are ≥ 18 years of age will be randomized to receive ivonescimab 10 milligrams per kilogram (mg/kg) or ivonescimab 20 mg/kg in combination with carboplatin and etoposide. Ivonescimab is a type of drug called a bispecific antibody. Antibodies are proteins that specifically recognize and bind to other types of proteins called antigens. Antibodies and antigens can work together to help the immune system fight cancer cells. Bispecific antibody, meaning it targets two different molecules at the same time. Ivonescimab is a new drug that may help the immune system attack cancer cells and may also block certain pathways that cancer uses to grow and spread. This dual action of ivonescimab aims to help the immune system to fight the cancer and also disrupt tumor growth by blocking blood vessel formation that tumors use to grow. Participants will receive induction with 4 cycles of ivonescimab (dose determined by randomization) with standard of care carboplatin and etoposide followed by maintenance therapy with ivonescimab at the same dose received during induction. Treatment will continue until disease progression, unacceptable toxicity or participant withdrawal. The purpose of this study is to determine what dose of ivonescimab works best in combination with carboplatin and etoposide chemotherapy in ES-SCLC. We will also examine the side effects, good and bad, associated with ivonescimab.
Conditions Studied
Interventions
- DRUG Ivonescimab 10 mg/kg
- DRUG Ivonescimab 20 mg/kg
Study Locations (1)
Wisconsin
- Aspirus Cancer Center Wausau - Wausau
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-02 |
| Est. Completion | 2030-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07057791
The ClinicalTrials.gov registry entry for NCT07057791 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PrECOG, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Extensive Stage Lung Small Cell Cancer appearing as the primary indexed condition, and to 2 interventions - of which Ivonescimab 10 mg/kg is the first listed.
NCT07057791 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT07057791 about?
NCT07057791 is a clinical study titled "Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer". Eligible untreated participants with Extensive Stage Small Cell Lung Cancer (ES-SCLC) who are ≥ 18 years of age will be randomized to receive ivonescimab 10 milligrams per kilogram (mg/kg) or ivonescimab 20 mg/kg in combination with carboplatin and etoposide. Ivonescimab is a type of drug called a ...
What is the current status of trial NCT07057791?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2026-02. Estimated completion is 2030-01.
What conditions does trial NCT07057791 study?
This clinical trial studies the following conditions: Extensive Stage Lung Small Cell Cancer.
What interventions are being tested in trial NCT07057791?
The interventions under investigation include: Ivonescimab 10 mg/kg (DRUG), Ivonescimab 20 mg/kg (DRUG).
Who is sponsoring clinical trial NCT07057791?
This trial is sponsored by PrECOG, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07057791 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.